Evidence map›Paper›PMID 40500315›Full record

ArticleNPJ precision oncology2025

Overcoming intra-tumoral heterogeneity for biomarker discovery in the high-grade serous ovarian cancer proteome.

Srikanth S Manda, Maiken M Espersen, Cristina Mapagu, Natalie Bouantoun, Jessica Boros, Yoke-Eng Chiew, Sivatharsny Srirangan, Swetansu Pattnaik, Catherine J Kennedy, Alison H Brand and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Srikanth S MandaProCan®, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, NSW, Australia.
Maiken M EspersenCentre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW, Australia.
Cristina MapaguCentre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW, Australia.
Natalie BouantounCentre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW, Australia.
Jessica BorosCentre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW, Australia.
Yoke-Eng ChiewCentre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW, Australia.
Sivatharsny SriranganCentre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW, Australia.
Swetansu PattnaikGarvan Institute for Medical Research, Darlinghurst, Sydney, NSW, Australia.
Catherine J KennedyCentre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW, Australia.
Alison H BrandFaculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Dale W GarsedPeter MacCallum Cancer Center, Melbourne, VIC, Australia.
Ahwan PandeyPeter MacCallum Cancer Center, Melbourne, VIC, Australia.
David D L BowtellPeter MacCallum Cancer Center, Melbourne, VIC, Australia.
Australian Ovarian Cancer Study (AOCS) Group
Natasha LucasProCan®, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, NSW, Australia.
Dylan XavierProCan®, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, NSW, Australia.
Sadia MahboobProCan®, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, NSW, Australia.
Daniel Bucio-NobleProCan®, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, NSW, Australia.
Brett TullyProCan®, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, NSW, Australia.
Peter G HainsProCan®, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, NSW, Australia.
Phillip J RobinsonProCan®, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, NSW, Australia.
Qing ZhongProCan®, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, NSW, Australia.
Roger ReddelProCan®, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, NSW, Australia.
Anna DeFazio *Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW, Australia. anna.defazio@sydney.edu.au.
Rosemary L Balleine *ProCan®, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, NSW, Australia. rosemary.balleine@sydney.edu.au.

Funding

Cancer Council NSW IG 18-01Cancer Institute NSW 2017/TPG001, REG171150Cancer Institute NSW Early Career Fellowship 2017/ECF004Medical Research Futures Fund MRFF-PDNational Health and Medical Research Council (NHMRC) of Australia European Union grant GNT1170739National Health and Medical Research Council of Australia Grants 1186505 and 2029088National Health and Medical Research Council of Australia ID400413, ID400281NHMRC Fellowship GNT1137064NSW Ministry of Health CMP-01U.S. Army Medical Research and Materiel Command DAMD17-01-1-0729U.S. Army Medical Research and Materiel Command Ovarian Cancer Research Program Award No. W81XWH-21-1-0401Victorian Cancer Agency MCRF22018
6 · The paper itself

Abstract

Improved biomarkers of treatment response are needed for patients with high-grade serous ovarian cancer (HGSC). A challenge is substantial anatomical site-to-site variation in expression. We completed data-independent acquisition-mass spectrometry (DIA-MS) analysis of 404 fresh frozen and 78 formalin-fixed, paraffin-embedded HGSC tissue samples from the ovary (adnexal) and a common secondary site (omentum) in 11 patients. This was compared with mutation testing, gene expression, and whole-genome copy number profiling. Proteins with relatively stable intra- and variable inter-individual expression (n = 1651), included a 52-protein module reflecting interferon-mediated tissue inflammation, indicative of a cGAS-STING pathway cytosolic double-stranded (ds) DNA response. The dsDNA sensing/inflammation score was higher in the omentum compared with the ovary. Ovarian HGSC samples showed marked inter-individual differences in inflammatory and immune responses to DNA damage. Stable discriminative features of the HGSC proteome, a prerequisite for clinical predictive biomarkers, are detectable in ovary (adnexal) tissue samples.

Identifiers

PMID40500315
PMCPMC12159146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.